| Budget Amount *help |
¥177,190,000 (Direct Cost: ¥136,300,000、Indirect Cost: ¥40,890,000)
Fiscal Year 2020: ¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2019: ¥36,400,000 (Direct Cost: ¥28,000,000、Indirect Cost: ¥8,400,000)
Fiscal Year 2018: ¥33,020,000 (Direct Cost: ¥25,400,000、Indirect Cost: ¥7,620,000)
Fiscal Year 2017: ¥40,170,000 (Direct Cost: ¥30,900,000、Indirect Cost: ¥9,270,000)
Fiscal Year 2016: ¥50,050,000 (Direct Cost: ¥38,500,000、Indirect Cost: ¥11,550,000)
|
|---|
| Outline of Final Research Achievements |
Wnts are secretory proteins which are essential for organogenesis during the embryonic period. After birth, Wnt signaling activated by Wnt ligands are involved in maintaining organ homeostasis. It is known that abnormal activation of Wnt signaling due to gene alterations of its components causes cancer, however, its molecular mechanisms are not fully understood and development of anti-cancer drugs has not yet been progressed. In this research, we analyzed the roles of new Wnt signaling-related molecules and pathways that we identified in tumorigenesis. We elucidated their mechanisms using cultured cells and model mice and clarified clinical significance using human specimens and databases. Furthermore, we developed anti-sense oligo nucleotides and antibodies against the molecules we found and we showed their efficacy of cancer therapy using model mice.
|
